PHAT vs RLMD: stock comparison and AI forecast
Phathom Pharmaceuticals, Inc. (PHAT) and Relmada Therapeutics, Inc. (RLMD) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
PHAT Phathom Pharmaceuticals, Inc.
- Market Cap
- $413M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
RLMD Relmada Therapeutics, Inc.
- Price
- $3.77 -49.3% · 6M
- Market Cap
- $402M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- PHAT and RLMD have similar market capitalizations ($413M and $402M).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | PHAT | RLMD |
|---|---|---|
| Market Cap | $413M | $402M |
| P/B Ratio | – | 1.95x |
| EPS | $-0.42 | $-1.26 |
| Book Value/Share | – | $1.94 |
| Revenue/Share | $3.38 | – |
| FCF/Share | $-0.26 | – |
Profitability & Margins
| Metric | PHAT | RLMD |
|---|---|---|
| ROIC | -15.0% | -30.8% |
| Gross Margin | 80.7% | – |
| Operating Margin | -9.3% | – |
| EBT Margin | -31.6% | – |
Financial Health
| Metric | PHAT | RLMD |
|---|---|---|
| Current Ratio | 1.76x | 29.52x |
| Quick Ratio | 1.72x | – |
| D/E Ratio | – | 0.06x |
| Financial Leverage | – | 1.06x |
| Interest Coverage | -0.0x | -21.3x |
| Working Capital | $133M | $212M |
Cash Flow
| Metric | PHAT | RLMD |
|---|---|---|
| Operating Cash Flow | -$21M | -$46M |
| Free Cash Flow | -$21M | – |
| Capital Spending | -$300K | – |
| FCF/Sales | -7.7% | – |
| CapEx/Sales | 0.1% | – |
Operational Efficiency
| Metric | PHAT | RLMD |
|---|---|---|
| Asset Turnover | 0.80x | – |
| Receivables Turnover | 2.5x | – |
| Inventory Turnover | 7.0x | – |
| Fixed Assets Turnover | 294.0x | – |
| Days Sales Outstanding | 143 days | – |
| Days Inventory | 52 days | – |
| Payables Period | 76 days | – |
| Cash Conversion Cycle | 119 days | – |
Income Statement
| Metric | PHAT | RLMD |
|---|---|---|
| Total Revenue | $275M | – |
| Operating Income | -$25M | -$65M |
| R&D Expense | $32M | $29M |
| SG&A Expense | $215M | – |
| Cost of Goods Sold | $53M | – |
Dividend & Shareholder Information
| Metric | PHAT | RLMD |
|---|---|---|
| Shares Outstanding | 81M | 107M |
PHAT vs RLMD: stock comparison and AI forecast
Which is bigger, PHAT or RLMD?
PHAT and RLMD have similar market capitalizations ($413M and $402M).
Which one does Intratio's AI model rank higher, PHAT or RLMD?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.